Trial Profile
An Open-Label Study to Evaluate the Safety and Efficacy of the Coadministration of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) With Ribavirin (RBV) in Adults With Chronic Hepatitis C Virus Genotype 4 Infection in Egypt
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 16 Jun 2019
Price :
$35
*
At a glance
- Drugs Ombitasvir/paritaprevir/ritonavir (Primary) ; Ribavirin
- Indications Hepatitis C
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms Agate-II
- Sponsors AbbVie
- 04 Aug 2016 Status changed from active, no longer recruiting to completed.
- 17 Apr 2016 Interim results presented at The International Liver Congress™ 2016
- 16 Apr 2015 Status changed from recruiting to active, no longer recruiting, according to to ClinicalTrials.gov record.